Compare Five9 Inc (FIVN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Merck & Co., Inc. — how do they compare? Five9 Inc trades at $24.86 (market cap $1.90B), while Merck & Co., Inc. trades at $127.88 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 160.7× Five9 Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| FIVN | MRK | |
|---|---|---|
Market Cap | $1.90B | $305.29B |
Sector | Technology | Health |
52-Week High | $29.16 | $129.52 |
52-Week Low | $13.61 | $77.60 |
Enterprise Value | $1.98B | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.05, down 2.07% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals, with revenue growing from $779M in 2022 to $1.15B in 2025 and turning profitable with net income of $39.42M. Recent news highlights AI product launches and workplace awards, while legal scrutiny on insider conduct persists.
The stock presents a positive outlook with strong analyst support (61% buy ratings) and a consensus price target of $27.00, offering ~8% upside. Key risks include negative net cash flow, high debt levels, and ongoing legal investigations into insider fiduciary duties that could pressure sentiment.
MRK trades at $127.65, up 5.67% today, reflecting strong momentum. The stock shows a bullish technical signal with moving averages supporting the uptrend. Fundamentally, the company reported robust 2025 results with revenue of $65.01B and net income of $18.25B, and recently announced the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline. Analyst consensus is strongly positive with a $137.30 price target.
The outlook for MRK is favorable, driven by earnings beats, strategic acquisitions, and solid profitability. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. The stock presents a growth opportunity with upside to the consensus target, though investors should monitor integration of new acquisitions and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
